Biogen Idec's (BIIB) hemophilia drug candidate met goals in a late-stage trial. The drug increases the interval between needed doses, the key competitive advantage in that space. It expects to file for FDA approval in the first half of next year. But the success was not as dramatic as some hoped. Shares fell 3.3% to 138.21.